Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%

Death (all causes) · previously untreated patients with mRCC

Interferon‐α plus bevacizumab showed no clear difference in 1‐year mortality median compared with standard targeted therapies (low certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 0.37 [0.13, 1.08]
1 study · 83 participants
Low

Quality of life · previously untreated patients with mRCC

The review found no eligible studies for this question.

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Adverse events (grade ≥ 3) · previously untreated patients with mRCC

Interferon‐α plus bevacizumab showed no clear difference in adverse events (grade ≥ 3) compared with standard targeted therapies (low certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.18 [0.85, 1.62]
1 study · 82 participants
Low